Vertex Pharmaceuticals (NASDAQ: VRTX) has a knack for finding profitable niches, and it looks like it's on track to do so again in the field of pain relief. With the latest clinical-trial data ...

Vertex Pharmaceuticals' pain relief program could be lucrative in the years ahead. Phase 3 clinical trials suggest the current medicine is likely to be approved for sale. Investors' high ...